NCT02246621: A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with inflammatory breast cancer; Patients with clinical evidence or a history of central nervous system (CNS) metastasis; Patients with leptomeningeal disease; Patients who are currently receiving or have previously received endocrine therapy or chemotherapy for locoregionally recurrent or metastatic breast cancer; Patients who have received prior treatment with everolimus or any CDK 4/6 inhibitor (e.g. Ibrance/palbociclib, Verzenio/abemaciclib, Kisqali/ribociclib)

Comments are closed.

Up ↑